Febuxostat-d9
- Product Name
- Febuxostat-d9
- CAS No.
- 1246819-50-0
- Chemical Name
- Febuxostat-d9
- Synonyms
- TMX 67-d9;TEI 6720-d9;Febuxostat-d;Febuxostat-d9;[2H9]-Febuxostat;Dapagliflozin Impurity 138;Febuxostat-d9 (2-methylpropoxy-d9);2-(3-Cyano-4-isobutyloxyphenyl-d9)-4-Methyl-5-thiazolecarboxylic Acid;2-[3-Cyano-4-(2-Methylpropoxy-d9)phenyl]-4-Methyl-5-thiazolecarboxylic Acid;Febuxostat D9Q: What is Febuxostat D9 Q: What is the CAS Number of Febuxostat D9 Q: What is the storage condition of Febuxostat D9 Q: What are the applications of Febuxostat D9
- CBNumber
- CB22508843
- Molecular Formula
- C16H16N2O3S
- Formula Weight
- 316.37484
- MOL File
- 1246819-50-0.mol
Febuxostat-d9 Property
- Melting point:
- >201°C (dec.)
- storage temp.
- Refrigerator
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- form
- Solid
- color
- White to Off-White
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P330Rinse mouth.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 25033
- Product name
- Febuxostat-d9
- Purity
- ≥99% deuterated forms (d1-d9)
- Packaging
- 1mg
- Price
- $261
- Updated
- 2024/03/01
- Product number
- F229002
- Product name
- Febuxostat-d9
- Packaging
- 1mg
- Price
- $160
- Updated
- 2021/12/16
- Product number
- 3669AH
- Product name
- Febuxostat-D9
- Packaging
- 1mg
- Price
- $471
- Updated
- 2021/12/16
- Product number
- AA009CF5
- Product name
- Febuxostat-d9
- Purity
- ≥99%deuteratedforms(d<sub>1</sub>-d<sub>9</sub>)
- Packaging
- 1mg
- Price
- $394
- Updated
- 2021/12/16
Febuxostat-d9 Chemical Properties,Usage,Production
Description
Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.
Uses
Febuxostat-d9 is a Labeled compound, intended for use as an internal standard for the quantification of Febuxostat by GC- or LC-mass spectrometry.
Uses
Labelled Febuxostat (F229000). Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout.